メモ〜リンパ腫関係
参考文献・サイト
- イブリツモマブでびまん性大細胞型B細胞リンパ腫の95％が完全寛解：日経メディカル オンライン
- イットリウム（90Y）イブリツモマブ チウキセタン（遺伝子組換え）注射液調製用：[がん情報サービス 医療関係者の方へ]
- A. Hagenbeek1, and V. Lewington (2005) "Report of a European consensus workshop to develop recommendations for the optimal use of 90Y-ibritumomab tiuxetan (Zevalin®) in lymphoma." Annals of Oncology 16(5), 786-792. doi: 10.1093/annonc/mdi148
- E. Lopci, I. Santi, E. Derenzini, C. Fonti, G. Savelli, F. Bertagna, M. Bellò, B. Botto, D. Huglo, F. Morschhauser, P. Zinzani and S. Fanti (2010) "FDG–PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study." Annals of Oncology 21(9), 1877-1883. doi: 10.1093/annonc/mdq024
- P. L. Zinzani, M. Tani, S. Fanti, V. Stefoni, G. Musuraca, P. Castellucci, E. Marchi, M. Farsad, M. Fina, C. Pellegrini, L. Alinari, E. Derenzini, A. de Vivo, F. Bacci, S. Pileri and M. Baccarani (2008) "A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients." Annals of Oncology 19(4), 769-773. doi: 10.1093/annonc/mdm560